Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies : From Concept to Practice
Intro -- Precision Cancer Therapies -- Contents -- List of Contributors -- Volume Foreword -- Volume Preface -- Series Preface -- Section I Historical Perspective -- 1 The Distinguished History of Immunotherapy Development in Cancer -- Take Home Messages -- Introduction -- The Beginnings of Immunotherapy -- The Central Role of the Immune System -- Cytokines -- Antibody Based Therapy -- Immune Checkpoint Therapy -- Vaccines -- CAR T-cells and Adoptive Cell Therapy -- Summary -- Must Reads -- References -- Section II Targeting Cell Surface Receptors -- 2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage -- Take Home Messages -- Introduction -- Magic Bullets -- Monoclonal Antibodies -- Proof of Concept - Anti-idiotype mAb -- Chimeric, Humanized, and Human mAb -- Rituximab -- Anti-lymphoma mAb Mechanisms of Action -- Target Epitopes -- Enhancing mAb Effector Function -- Alternative Target Antigens -- Alternative Strategies to Leverage the Unique Aspects of mAb Therapy -- Radioimmunotherapy Based on Anti-sera -- Mab-based Radioimmunotherapy -- Radioimmunotherapy of B Cell Lymphoma -- Immunotoxins -- Antibody-drug Conjugates -- Retargeting T Cells -- Bispecific Antibodies -- Chimeric Antigen Receptor T Cells -- Bispecific Antibodies versus CAR-T -- Immune Checkpoint Blockade in Lymphoma -- Remaining Questions -- Conclusion -- Must Reads -- References -- 3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 -- Take Home Messages -- Introduction -- Anti-CD20 Monoclonal Antibody Development -- Rituximab -- Ofatumumab -- Ublituximab -- Obinutuzumab -- Resistance to Anti-CD20 Monoclonal Antibodies -- Combinations Using Bruton Tyrosine Kinase Inhibitor and Anti-CD20 Monoclonal Antibodies -- Radiolabeled Anti-CD20 Antibodies: I-131 Tositumomab and Y-90 Ibritumomab Tiuxetan..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2024 ©2024 |
|---|---|
| Erschienen: |
Newark: John Wiley & Sons, Incorporated ; 2024 ©2024 |
| Ausgabe: |
1st ed. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Connor, Owen A. [VerfasserIn] |
|---|
| Links: |
ebookcentral.proquest.com [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| Anmerkungen: |
Description based on publisher supplied metadata and other sources |
|---|
| Umfang: |
1 online resource (492 pages) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1881518922 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1881518922 | ||
| 003 | DE-627 | ||
| 005 | 20240228105429.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240223s2024 xx |||||o 00| ||eng c | ||
| 020 | |a 9781119824558 |9 978-1-119-82455-8 | ||
| 035 | |a (DE-627)1881518922 | ||
| 035 | |a (DE-599)KEP100844022 | ||
| 035 | |a (EBC)EBC31165239 | ||
| 035 | |a (EBL)EBL31165239 | ||
| 035 | |a (EBP)100844022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | |a 616.99446 | |
| 100 | 1 | |a O'Connor, Owen A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies |b From Concept to Practice |
| 250 | |a 1st ed. | ||
| 264 | 1 | |a Newark |b John Wiley & Sons, Incorporated |c 2024 | |
| 264 | 4 | |c ©2024 | |
| 300 | |a 1 online resource (492 pages) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Description based on publisher supplied metadata and other sources | ||
| 520 | |a Intro -- Precision Cancer Therapies -- Contents -- List of Contributors -- Volume Foreword -- Volume Preface -- Series Preface -- Section I Historical Perspective -- 1 The Distinguished History of Immunotherapy Development in Cancer -- Take Home Messages -- Introduction -- The Beginnings of Immunotherapy -- The Central Role of the Immune System -- Cytokines -- Antibody Based Therapy -- Immune Checkpoint Therapy -- Vaccines -- CAR T-cells and Adoptive Cell Therapy -- Summary -- Must Reads -- References -- Section II Targeting Cell Surface Receptors -- 2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage -- Take Home Messages -- Introduction -- Magic Bullets -- Monoclonal Antibodies -- Proof of Concept - Anti-idiotype mAb -- Chimeric, Humanized, and Human mAb -- Rituximab -- Anti-lymphoma mAb Mechanisms of Action -- Target Epitopes -- Enhancing mAb Effector Function -- Alternative Target Antigens -- Alternative Strategies to Leverage the Unique Aspects of mAb Therapy -- Radioimmunotherapy Based on Anti-sera -- Mab-based Radioimmunotherapy -- Radioimmunotherapy of B Cell Lymphoma -- Immunotoxins -- Antibody-drug Conjugates -- Retargeting T Cells -- Bispecific Antibodies -- Chimeric Antigen Receptor T Cells -- Bispecific Antibodies versus CAR-T -- Immune Checkpoint Blockade in Lymphoma -- Remaining Questions -- Conclusion -- Must Reads -- References -- 3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 -- Take Home Messages -- Introduction -- Anti-CD20 Monoclonal Antibody Development -- Rituximab -- Ofatumumab -- Ublituximab -- Obinutuzumab -- Resistance to Anti-CD20 Monoclonal Antibodies -- Combinations Using Bruton Tyrosine Kinase Inhibitor and Anti-CD20 Monoclonal Antibodies -- Radiolabeled Anti-CD20 Antibodies: I-131 Tositumomab and Y-90 Ibritumomab Tiuxetan. | ||
| 700 | 1 | |a Ansell, Stephen M. |e mitwirkender |4 ctb | |
| 700 | 1 | |a Gribben, John G. |e mitwirkender |4 ctb | |
| 776 | 1 | |z 9781119824541 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781119824541 |
| 856 | 4 | 0 | |u https://ebookcentral.proquest.com/lib/kxp/detail.action?docID=31165239 |m X:EBC |x Aggregator |z lizenzpflichtig |
| 912 | |a ZDB-30-PQE | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a ISIL_DE-8 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a ISIL_DE-Brg3 | ||
| 912 | |a GBV_ILN_736 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a ISIL_DE-289 | ||
| 951 | |a BO | ||
| 953 | |2 045F |a 616.99446 | ||
| 980 | |2 24 |1 01 |x 0008 |b 4503104918 |h olr-ddaebc |k Diesen Titel können Sie über den Zugriffslink zunächst für kurze Zeit nutzen (1 Campuszugriff zur Zeit möglich) und bei weiterem Bedarf nach persönlicher Registrierung auf der nachfolgenden Seite der Zentralbibliothek zur dauerhaften Anschaffung vorschlagen. Wir werden Sie zügig über die Bereitstellung informieren. |y z |z 22-03-24 | ||
| 980 | |2 206 |1 01 |x 3350 |b 4503142852 |c 00 |f --%%-- |d Online-Ressource |e --%%-- |j --%%-- |h OLR-EBL |k If you are a ThHF affiliate and the E-Book is not fully accessible, please send us a purchase or short time loan request. All others: Inter-library loans and guest access on campus premises is not possible. |y zh |z 23-03-24 | ||
| 980 | |2 736 |1 01 |x 4736 |b 4490497105 |h EBC-Content |y zeg |z 23-02-24 | ||
| 980 | |2 2021 |1 01 |x DE-289 |b 4491128103 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |y l01 |z 26-02-24 | ||
| 981 | |2 24 |1 01 |x 0008 |r https://ebookcentral.proquest.com/lib/christianalbrechts/detail.action?docID=31165239 | ||
| 981 | |2 206 |1 01 |x 3350 |y Full Text only for ThHf affiliates |r https://thh-friedensau.idm.oclc.org/login?url=http://ebookcentral.proquest.com/lib/thhfriedensau/detail.action?docID=31165239 | ||
| 981 | |2 736 |1 01 |x 4736 |r https://ebookcentral.proquest.com/lib/staat/detail.action?docID=31165239 | ||
| 981 | |2 2021 |1 01 |x DE-289 |r https://ebookcentral.proquest.com/lib/kiz-uniulm/detail.action?docID=31165239 | ||
| 995 | |2 24 |1 01 |x 0008 |a olr-ddaebc | ||
| 995 | |2 206 |1 01 |x 3350 |a OLR-EBL | ||
| 995 | |2 736 |1 01 |x 4736 |a EBC-Content | ||